Correction to: KIFC1 is activated by TCF-4 and promotes hepatocellular carcinoma pathogenesis by regulating HMGA1 transcriptional activity.

In the original publication of this article [1], the indicated stages (I-II III-IV) were missing in the clinical stage part at both Table 1 and Table 2.

Correction to: J Exp Clin Cancer Res (2019) 38: 329

https://doi.org/10.1186/s13046-019-1331-8

In the original publication of this article [1], the indicated stages (I-II III-IV) were missing in the clinical stage part at both Table 1 and Table 2. The revised tables are shown below.

Table 1

Correlation expression of KIFC1 and clinicopathological parameters in 168 HCC cases in SYSUCC cohort

Variable	All cases (N = 168)	KIFC1 expression (%)		P values
		Low expression (N = 97)	High expression (N = 71)
Age (years)				0.763
≤ 51	90	51 (56.7)	39 (43.3)
> 51	78	46 (59.0)	32 (41.0)
Sex				0.849
Male	143	83 (58.0)	60 (42.0)
Female	25	14 (56.0)	11 (44.0)
AFP (ng/ml)				0.652
≤ 20	72	43 (59.7)	29 (40.3)
> 20	96	54 (56.3)	42 (43.7)
HBsAg				0.394
negative	11	5 (45.5)	6 (54.5)
positive	157	92 (58.6)	65 (41.4)
Cirrhosis				0.713
No	99	56 (56.6)	43 (43.4)
Yes	69	41 (59.4)	28 (40.6)
Necrosis				0.506
No	76	46 (60.5)	30 (39.5)
Yes	92	51 (55.4)	41 (44.6)
Clinical stage				0.009
I-II	111	72 (64.9)	39 (35.1)
III-IV	57	25 (43.9)	32 (56.1)
Histologic grade (WHO)				0.113
G1-G2	83	53 (63.9)	30 (36.1)
G3-G4*	85	44 (51.8)	41 (48.2)
Tumor size (cm)				0.031
≤ 5	73	49 (67.1)	24 (32.9)
> 5	95	48 (50.5)	47 (49.5)
Tumor multiplicity				0.688
Unifocal	128	75 (58.6)	53 (41.4)
Multifocal	40	22 (55.0)	18 (45.0)
Intravascular emboli				0.688
No	100	59 (59.0)	41 (41.0)
Yes	68	38 (55.9)	30 (44.1)
Recurrence				0.037
No	125	78 (62.4)	47 (37.6)
Yes	43	19 (44.2)	24 (55.8)

*:including 3 cases sarcomatoid liver cancer

Table 2

Univariate and multivariate analysis of different prognostic parameters in 168 HCC patients

Variable	Univariate analysis			Multivariate analysis
	All cases	Mean survival (months)	p Value	HR (95% CI)	p Value
Age (years)			0.339
≤ 51	90	49.799
> 51	78	69.089
Sex			0.061
Male	143	69.106
Female	25	43.696
AFP (ng/ml)			0.055
≤ 20	72	72.295
> 20	96	53.431
HBsAg			0.329
negative	11	59.111
positive	157	66.402
Cirrhosis			0.829
No	99	57.617
Yes	69	66.272
Necrosis			0.179
No	76	60.350
Yes	92	63.514
Clinical stage			0.000		0.000
I-II	111	65.813		1
III-IV	57	43.778		5.173 (2.456–10.894)
Histologic grade (WHO)			0.000		0.035
G1-G2	82	65.254		1
G3-G4*	86	55.882		2.334 (1.063–5.126)
Tumor size (cm)			0.017		0.915
≤ 5	73	74.428
> 5	95	49.049
Tumor multiplicity			0.000		0.478
Unifocal	128	61.089
Multifocal	40	50.483
Intravascular emboli			0.013		0.483
No	100	61.257
Yes	68	59.172
Recurrence			0.007		0.061
No	125	70.974
Yes	43	44.667
KIFC1			0.002		0.012
Low		74.153		1
High		45.568		2.371 (1.207–4.660)

*:including 3 cases sarcomatoid liver cancer

The authors sincerely apologize for the inconvenience caused to the readers.